Explore Accera. Discover progress.
Accera, Inc., is a privately held biotechnology company that develops therapies to treat central nervous system disorders. Our novel therapeutic approach, including a proprietary scientific platform, has led to breakthrough discoveries that positively impact patients and their families.
Axona®, a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease, is Accera’s first product to reach the market.
Learn more about how Axona may help people with mild to moderate Alzheimer’s at www.about-axona.com.
Axona is a non-drug prescription medical food for people with mild to moderate Alzheimer’s disease. It is the only therapy that addresses diminished cerebral glucose metabolism (DCGM), a crucial aspect of Alzheimer’s disease.
Accera’s proprietary scientific platform has led to innovative breakthroughs, including Axona. Learn more about how we are on the cutting-edge of scientific research.
Accera is a forward-thinking company looking to develop mutually beneficial partnerships with pharmaceutical companies and research universities. Discover why you should partner with Accera today.